Profound Medical Corp.
PRN.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 146.98% | 583.24% | -15.91% | 91.59% | -- |
| Total Other Revenue | -14.36% | 53.26% | 6.92% | 25.16% | 33.80% |
| Total Revenue | 43.13% | 86.76% | -0.99% | 82.14% | 107.86% |
| Cost of Revenue | 63.59% | 30.08% | -26.97% | 34.03% | 19.02% |
| Gross Profit | 34.74% | 119.85% | 13.86% | 113.97% | 199.49% |
| SG&A Expenses | 6.46% | 12.18% | 84.38% | 71.13% | 14.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.59% | 20.05% | 58.98% | 47.99% | 15.66% |
| Operating Income | 11.70% | 0.94% | -76.05% | -41.75% | 5.35% |
| Income Before Tax | -57.16% | 14.50% | -126.54% | -63.22% | 41.69% |
| Income Tax Expenses | 110.92% | -31.64% | 236.84% | 2.50% | -3.93% |
| Earnings from Continuing Operations | -65.25% | 14.82% | -126.84% | -62.85% | 42.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.25% | 14.82% | -126.84% | -62.85% | 42.90% |
| EBIT | 11.70% | 0.94% | -76.05% | -41.75% | 5.35% |
| EBITDA | 10.45% | 0.20% | -79.61% | -44.26% | 5.42% |
| EPS Basic | -39.27% | 30.57% | -84.46% | -31.73% | 52.64% |
| Normalized Basic EPS | -32.54% | 30.33% | -84.30% | -32.01% | 51.67% |
| EPS Diluted | -39.27% | 30.57% | -84.46% | -31.73% | 52.64% |
| Normalized Diluted EPS | -32.54% | 30.33% | -84.30% | -32.01% | 51.67% |
| Average Basic Shares Outstanding | 18.64% | 22.70% | 22.96% | 23.65% | 20.60% |
| Average Diluted Shares Outstanding | 18.64% | 22.70% | 22.96% | 23.65% | 20.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |